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Endogenous mechanisms in the resolution of acute
inflammationareof interestbecauseexcessive inflam-
mation underlies many pathologic abnormalities. We
report an aspirin-triggered DHA metabolome that
biosynthesizes a potent product in inflammatory ex-
udates and human leukocytes, namely aspirin-trig-
gered Neuroprotectin D1/Protectin D1 [AT-(NPD1/
PD1)]. The complete stereochemistry of AT-(NPD1/
PD1) proved to be 10R,17R-dihydroxydocosa-4Z,7Z,
11E,13E,15Z,19Z-hexaenoic acid. The chirality of hy-
droxyl groups and geometry of the conjugated triene
system essential for bioactivity were established by
matching biological materials with stereochemically
pure isomers prepared by organic synthesis. AT-
(NPD1/PD1) reduced neutrophil (PMN) recruitment in
murine peritonitis in a dose-dependent fashionwhere-
by neither a D15-trans-isomer nor DHA was effective.
With humancells, AT-(NPD1/PD1) decreased transen-
dothelial PMNmigrationaswell as enhancedefferocy-
tosis of apoptotic human PMN by macrophages.
These results indicate that AT-(NPD1/PD1) is a potent
anti-inflammatory proresolving molecule.
INTRODUCTION
Neutrophils (PMN) are first to arrive in the acute inflammatory
response and play an important protective role in innate immu-
nity and host defense. However, excessive accumulation of
PMN within tissues can lead to tissue damage, amplification of
the inflammatory response, injury from within, and prolongation
of the signs of inflammation (Majno et al., 1982). The control of
neutrophil infiltration is of wide interest, as new anti-inflamma-
tory agents are needed to control excess neutrophil responses
that can give rise to chronic inflammatory diseases (Dinarello,
2010). Along these lines, evidence was sought for the endoge-
nous mechanism(s) controlling PMN infiltration and natural
tissue resolution, because protective PMN (i.e., acute inflamma-
tory responses) are programmed to be self-limited and tightly
controlled (Serhan et al., 2002; Serhan and Savill, 2005). Lipid
mediators such as prostaglandins and leukotrienes play pivotal
roles in the initiation of acute inflammation (Samuelsson, 1983),976 Chemistry & Biology 18, 976–987, August 26, 2011 ª2011 Elseviwhereas resolvins and protectins promote and stimulate active
resolution (Bazan et al., 2010; Serhan et al., 2002; Serhan and
Savill, 2005). In excess, prostaglandins and leukotrienes are
proinflammatory (Samuelsson, 1983).
Unlike many of the current anti-inflammatory agents, which
delay complete resolution and are considered toxic to this vital
process (i.e., resolution toxic) (Gilroy et al., 1999; Schwab
et al., 2007), aspirin is unique in that it jump-starts resolution
by novel previously unrecognized mechanisms that involve the
biosynthesis of aspirin-triggered (AT) lipid mediators (Gilroy
and Perretti, 2005; Serhan, 2007). For example, aspirin-triggered
lipoxins were the first aspirin-triggered lipid mediators uncov-
ered (Cla`ria and Serhan, 1995). Aspirin is well appreciated for
its ability to inhibit COX-1 and inactivate this enzyme, blocking
both prostaglandin and thromboxane production in cells that
possess these biosynthetic pathways (Samuelsson, 1982;
Vane, 1982). Themechanism of aspirin’s action involves acetyla-
tion of COX within the enzyme’s catalytic region. This prevents
alignment of the substrate arachidonic acid for oxygenation
within the catalytic center that produces the prostaglandin endo-
peroxide intermediate (PGG2), which is required for the biosyn-
thesis of both thromboxanes and prostaglandins via COX-1.
Aspirin’s action within cells that possess COX-2 is different.
The catalytic region of COX-2 is larger than that of COX-1, and
when it is acetylated by aspirin, the biosynthesis of endoper-
oxide is blocked. Yet, unlike COX-1, acetylated COX-2 remains
active, producing lipoxygenase-like products such as 15-HETE
from arachidonic acid, but with the oxygen insertion in the R
configuration rather than S as is the case with lipoxygenases
(Cla`ria and Serhan, 1995; Rowlinson et al., 2000). The COX-2–
produced 15R-HETE is converted to the potent bioactive
aspirin-triggered lipoxins that retain the carbon 15 position
alcohol in the R configuration, as in AT-15R-(epi)-lipoxin A4,
which is produced in vivo in humans (Chiang et al., 2004).
AT-LXA4 is longer acting in vivo than LXA4 because the 15R
alcohol is less efficiently enzymatically converted to the inactive
15-oxo-LXA4 metabolite (Serhan et al., 1993). This aspirin-trig-
gered pathway was recently demonstrated in humans, where
low-dose aspirin is anti-inflammatory and triggers the endoge-
nous biosynthesis of AT-LXA4, which, in turn, stops PMN infiltra-
tion in skin blisters (Morris et al., 2009 and references within).
Docosahexaenoic acid (DHA), an omega-3 fatty acid, is en-
riched in neural tissues (Bazan, 2006; Lands, 2005; Salem
et al., 2001) and is also converted to potent mediators, including
resolvins and protectins, in resolving inflammatory exudates
(Serhan et al., 2002). One of the protectins, 10,17-docosatriene,er Ltd All rights reserved
Figure 1. Synthetic Protectins Prepared for Lipidomics and Matching
Neuroprotectin D1/protectin D1, aspirin-triggered neuroprotectin D1/protectin D1, and related isomers are shown.
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of PMN infiltration, reducing stroke-mediated tissue damage
(Marcheselli et al., 2003; Serhan et al., 2002). Given its potent
protective actions in the retina and brain, we initially termed this
DHA-derived mediator neuroprotectin D1 (NPD1) (Bazan et al.,
2010; Mukherjee et al., 2004; Stark and Bazan, 2011). Because
this potent chemical mediator has a broader range of activities
in the immune, cardiovascular, and renal systems, for nonneuro-
nal local biosynthesis and actions, we used the name protectin
D1 (PD1). The complete stereochemistry and anti-inflammatory
actions of NPD1/PD1 (10R,17S-dihydroxy-docosa-4Z,7Z,11E,
13E,15Z,19Z-hexanenoic acid) were unambiguously established
(Serhan et al., 2006), and its immunoregulatory roles were
demonstrated (Ariel et al., 2005, 2006; Serhan and Savill, 2005).
Of interest, recent results indicate that NPD1/PD1 is also reno-
protective (Hassan and Gronert, 2009), induces corneal nerve
regeneration (Cortina et al., 2010), and stimulates cardiac and
neural stem cell differentiation at nanomolar potencies (Yanes
et al., 2010).
Aspirin-triggered resolvins and related u-3–derived mediators
were first identified in self-limited resolving murine exudates as
well as brain, and their production was documented with isolated
humancells (i.e., leukocytes,microglia, andvascularcells) (Serhan
et al., 2002) and in stroke (Marcheselli et al., 2003). The complete
stereochemistry and bioactions of aspirin-triggered 10,17-doco-
satriene remained tobeestablished.Here,we report the complete
stereochemistry of the aspirin-triggered protectin pathway from
murine exudates and human PMN and report that AT-(NPD1/
PD1) displays potent protective bioactions comparable to
NPD1/PD1 in vitro and in vivo, reducing both PMN infiltration
and enhancing the removal of apoptotic PMN by macrophages.
RESULTS
Stereochemical Characterization of Synthetic
AT-(NPD1/PD1) Isomers
The structure and stereochemistry of each of the synthetic AT-
(NPD1/PD1) stereoisomers (Figure 1) was fully confirmed byChemistry & Biology 18, 97NMR analysis (Figure 2). Because the hydroxyl group chirality
was directly incorporated from an enantiomerically pure starting
material, the final R/S assignments at the C-10 and C-17 posi-
tions were made unambiguously (Figure 2A). The isomeric purity
and double bond geometry for each stereoisomer was con-
firmed by NMR spectroscopy. The chemical shifts and coupling
constants for each stereoisomer showed a distinct and charac-
teristic profile in the NMR olefinic region in the NMR (Figures
2B–2D).
Stereochemical Assignment of AT-(NPD1/PD1)
To determine the complete stereochemical assignment and bio-
actions of AT-(NPD1/PD1), we directly compared the physical
and biological properties of DHA-derived AT-(NPD1/PD1) and
related 10,17 dihydroxy-docosatriene stereoisomers produced
by leukocytes to those prepared in stereochemically pure
form by total organic synthesis. Figure 3A is a representative
MRM analysis of 10R,17R-dihydroxydocosa-4Z,7Z,11E,13E,
15Z,19Z-hexaenoic acid (denoted as synthetic AT-(NPD1/
PD1)), 10S,17R-dihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hex-
aenoic acid (denoted as 10S,17R-PD1 isomer), and NPD1/PD1.
Synthetic AT-(NPD1/PD1) and NPD1/PD1 were separated in
these liquid chromatography conditions (for details, see Experi-
mental Procedures), with retention times at 8.2 and 12.0 min
respectively, whereas the 10S,17R-PD1 isomer coeluted with
NPD1/PD1. This 10S,17R-PD1 isomer was found to be biologi-
cally inactive (Serhan et al., 2006) and did not coelute with the
aspirin-triggered product; therefore, we next focused on deter-
mining the complete stereochemistry of AT-(NPD1/PD1). As ex-
pected, spectroscopic properties of synthetic AT-(NPD1/PD1),
D15-trans-AT-(NPD1/PD1), and NPD1/PD1 are essentially iden-
tical (Figures 3B—3D, respectively). The UV spectra of synthetic
AT-(NPD1/PD1), D15-trans-AT-(NPD1/PD1), and NPD1/PD1 dis-
played essentially the same triplet bands of absorbance with
lmax
MeOH at271 nm. Also, tandemmass spectra of these three
compounds shared essentially the same fragmentation patterns.
The major ions of three tandem mass spectra were assigned
as following: m/z 341, 323, 315, 297, and 279 were neutral loss6–987, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 977
Figure 2. Strategy for the Total Organic Synthesis of Isomerically Pure Protectin Isomers and Their Stereochemical Assignment by NMR
Spectroscopy
(A) The total synthesis of AT-(NPD1/PD1) started with the epoxide opening of the R-glycidol derivative 1 bymetallated derivatives of alkynes 2 and 3, leading after
several steps to the synthesis of key intermediates 4 and 5, which were subjected to cross-coupling to form the acetylenic precursor 6, which after selective
hydrogenation and ester hydrolysis afforded AT-(NPD1/PD1).
(B–D) The NMR assignments of the olefinic region of three AT-(NPD1/PD1) stereoisomers show the anticipated chemical shifts and coupling constants for each
isomer.
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carboxyl group of each compound (see figure insets); m/z 153,
181, 206, and their corresponding neutral loss ions, m/z 163
and 188, originated from fragmentations around C-10; and the
cleavages between C-16 and C-17 generated m/z 261 and its
neutral loss m/z 217. These results are consistent with earlier
findings (Hong et al., 2003; Serhan et al., 2006) and also further
confirmed the chemical integrity of synthetic AT-(NPD1/PD1).
Together, synthetic AT-(NPD1/PD1) and NPD1/PD1 were able
to be discriminated using their reverse-phase liquid chromatog-
raphy retention times, which were different (Figure 3A), whereas
their UV and mass spectra were virtually indistinguishable, as
was that of the biologically inactive AT-(NPD1/PD1) isomer using
LC-UV-MS-MS retention times (vide infra).
Matching of Biologic AT-(NPD1/PD1) with Synthetic
AT-(NPD1/PD1) Candidates
AT-(NPD1/PD1) was identified in resolving murine exudates
treated with aspirin (Serhan et al., 2002). Hence, biologic AT-
(NPD1/PD1)wasobtained fromresolvingmurineexudates invivo.978 Chemistry & Biology 18, 976–987, August 26, 2011 ª2011 ElseviBriefly, peritonitis was initiated via intraperitoneal (i.p.) adminis-
trationof zymosanA (1mg/mouse), andexudateswereharvested
24 hr after injection (i.e., within the resolution phase; Bannenberg
et al., 2005). Exudates were subject to solid phase extraction
and were analyzed using LC-UV-MS-MS-based mediator lipido-
mics. RepresentativeMRM (m/z 359 >153) is shown in Figure 4A.
Among the candidates, synthetic AT-(NPD1/PD1) matched peak
I with retention time at 8.2 min (Figure 4B), which was confirmed
by coinjection (Figure 4C). Synthetic AT-(NPD1/PD1) gave a UV
spectrum and tandem mass spectrum that was essentially iden-
tical to the material beneath Peak I (Figures 4D and 4E), which
further confirmed the matching. AT-(NPD1/PD1) was also iso-
lated and identified from activated human leukocytes, namely,
aspirin-treated human PMN. A representative tandem mass
spectrum of the human PMN aspirin-triggered product is shown
in Figure 4F. Collectively, by matching biologic materials from
both human andmurine exudates AT-(NPD1/PD1) with synthetic
candidates, these results established the complete stereochem-
istry of endogenous AT-(NPD1/PD1) as 10R,17R-dihydroxydo-
cosa-4Z,7Z,10E,12E,14Z,19Z-hexaenoic acid.er Ltd All rights reserved
Figure 3. LC-MS-MS Lipidomics and Properties of Synthetic AT-(NPD1/PD1), NPD1/PD1, and Their Isomers
(A) MRM chromatogram (m/z 359 > 153) of coinjection of synthetic AT-(NPD1/PD1), 10S,17R-AT-(NPD1/PD1) isomer, and NPD1/PD1 is shown. AT-(NPD1/PD1)
and NPD1/PD1 separate in this LC system, with retention times of 8.2 and 12.0 min.
(B–D) Representative tandem mass and UV spectra of synthetic AT-(NPD1/PD1) (B), D15-trans-NPD1/PD1 (C), and NPD1/PD1 (D) are shown.
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The complete stereochemical assignment for AT-(NPD1/PD1)
also relied on determining in parallel its biological actions.
Earlier results indicated that NPD1/PD1 exerted potent anti-
inflammatory actions regulating leukocyte trafficking in murine
systems (Hong et al., 2003; Serhan et al., 2002, 2006). Hence,
we sought to compare directly the bioactions of NPD1/PD1 to
that of AT-(NPD1/PD1) performed in parallel with the physical
matching experiments (Figures 3 and 4). Synthetic AT-(NPD1/
PD1) limited PMN infiltration into the peritoneum in TNF-a–
stimulated peritonitis (Figure 5). Both NPD1/PD1 (0.1–10 ng)
and AT-(NPD1/PD1) (0.01–10.0 ng) proved to be significant
regulators of TNF-a–stimulated leukocyte infiltration into the
peritoneum. AT-(NPD1/PD1) reduced total leukocyte population
of the exudate, including PMN infiltrates (Figures 5A and 5B),
reaching a maximal reduction at 1 ng/mouse by as much as
50.4% ± 8.8%. The PMN population was also reduced (FiguresChemistry & Biology 18, 975C and 5D), with AT-(NPD1/PD1) reaching a maximal PMN
reduction at 1 ng/mouse (62.2% ± 7.8%). Representative flow
cytometry dot plots obtained with murine exudates indicated
a reduction in the Ly6G+CD11b+ population as compared to
TNF-a alone (Figure 5C, inset). Of note, the D15-trans-AT-
(NPD1/PD1) isomer did not reduce either the total exudate
leukocyte population or PMN infiltration (Figures 5B and 5D,
upper panels).
Recently, we found that NPD1/PD1 limited PMN infiltration in
zymosan A–initiated peritonitis (Serhan et al., 2006). Therefore,
we determined whether AT-(NPD1/PD1) also reduced PMN infil-
tration in zymosan A–stimulated peritonitis. Indeed, AT-(NPD1/
PD1) (0.1–100.0 ng) significantly reduced total leukocyte (Fig-
ure 5E), aswell asPMN infiltration (Figure 5F), reaching amaximal
reduction of 47.8% ± 10.0% and 49.1% ± 11.9%, respectively.
In comparison to AT-(NPD1/PD1) (1.0 and 10.0 ng), equal doses
of either the precursor DHA or D15-trans-AT-NPD1/PD1 did not6–987, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 979
Figure 4. LC-MS-MS Matching: Comparisons for Biologic and Synthetic AT-(NPD1/PD1)
(A) Graph shows representative MRM analysis (m/z 359 > 153) of incubations of cells from zymosan A–induced (1 mg/mouse) peritonitis with exudate taken at
24 hr. Cells (50 3 106/ml) were treated with aspirin (2 mM, 20 min, 37C), and then incubated with DHA (5 mg/ml) and A23187 (5 mM) for 20 min at 37C.
(B and C) Panels (B) (methyl formate fraction obtained from mouse peritonitis exudates) and (C) are representative MRM analyses (m/z 375 > 153) of synthetic
AT-(NPD1/PD1) and coinjection of synthetic AT-(NPD1/PD1).
(D and E) Graphs are representative online UV (insets) and tandem mass spectra of exudate AT-(NPD1/PD1) from mouse peritonitis exudates (D) and synthetic
AT-(NPD1/PD1) (E).
(F) Graph is representative tandem mass spectrum of AT-(NPD1/PD1) obtained from incubations of isolated human PMN. Human PMN (50 3 106/ml) were
incubated with TNF-a (100 ng/ml, 4 hr, 37C) followed by aspirin (2 mM), DHA (5 mg/ml), and A23187 (5 mM) for 20 min at 37C (n = 3).
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(Figures 5G and 5H). Together, these results indicate that AT-
(NPD1/PD1) regulates inflammatory responses induced by the
proinflammatory cytokine TNF-a and the TLR ligand, zymosan
A. Moreover, these results indicate that the actions of AT-
(NPD1/PD1) and NPD1/PD1 are stereospecific in limiting PMN
accumulation in vivo in both murine types of inflammation.980 Chemistry & Biology 18, 976–987, August 26, 2011 ª2011 ElseviAT-NPD1/PD1 Reduced Human PMN Transendothelial
Migration and Enhanced Efferocytosis
Because this aspirin-triggered compound reduces PMN infiltra-
tion in murine systems, we next questioned whether it affects
PMN transendothelial migration using isolated human cells
because this is the first committed step of leukocytes in acute
inflammation. AT-(NPD1/PD1) and NPD1/PD1 (0.1–10.0 nM)er Ltd All rights reserved
Figure 5. AT-(NPD1/PD1) Reduces Leukocyte Infiltration in Peritonitis: Direct Comparison to NPD1/PD1
(A–D) Peritonitis was initiated by peritoneal injection of 500 ng of TNF-a alone, TNF-a plus synthetic AT-(NPD1/PD1) (0.01–10.0 ng), or NPD1/PD1 (0.01–10 ng).
Peritoneal lavages were obtained at 4 hr and leukocytes were enumerated (see Experimental Procedures). Shown are total leukocyte numbers (A), dose-
response: percentage reduction of total leukocytes (B), total PMN numbers (C), and dose-response: percentage reduction of PMN infiltration (D). Representative
flow cytometry dot plots are shown (C, inset). TNF-a, gray bars; AT-(NPD1/PD1), black bars; NPD1/PD1, white bars. Values are mean ± SEM of n = 7.
(E–H) AT-(NPD1/PD1) dose response and direct comparison to DHA. Zymosan A alone (100 mg/mouse), zymosan A plus AT-(NPD1/PD1) (0.01–100 ng/mouse), or
zymosan A plus DHA (1 and 10 ng/mouse) were injected (i.p.) and lavages were obtained at 4 hr. Total exudate leukocyte (PMN, monocyte, lymphocyte) numbers
(E and G), and total PMN (F and H) are shown. Insets in (E) and (F) show percentage reduction in total leukocytes and PMN. Zymosan A, gray bars; AT-(NPD1/
PD1), black bars; DHA, white bars; D15-trans-AT-(NPD1/PD1), striped bars. All values are mean ± SEM of n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle;
Xp < 0.05, XXp < 0.01 AT-(NPD1/PD1) versus NPD1/PD1. Using one-way and two-way ANOVA indicated that AT-NPD1 and NPD1/PD1 were not significantly
different from each other (p > 0.05).
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transendothelial migration induced by LTB4 (Figure 6A). In
comparison, equal concentrations of the D15-trans isomer of
AT-(NPD1/PD1), where the conjugated triene portion of the
molecule was in the trans rather than cis configuration, did not
significantly reduce PMN transendothelial migration. Again in
this system, the precursor DHA did not reduce LTB4-stimulated
PMN-transendothelial migration (Figure 6A). To corroborate
these findings, we next used an electric cell-substrate imped-
ance sensing system (ECIS) that sensitively quantitates cellular
responses in two cell systems by real-time monitoring of barrier
impedance (Tsikitis et al., 2004). Both AT-(NPD1/PD1) and
NPD1/PD1 (1 nM) decreased LTB4-stimulated PMN-transendo-
thelial migration by 40% and 30%, respectively (Figure 6B).
AT-(NPD1/PD1) also enhanced the uptake of apoptotic human
PMN by human macrophages at concentrations as low as
0.1 nM, as did NPD1/PD1 when compared directly (Figures 6C
and 6D). The response was bell shaped and was consistent
with the dose-response relationship observed for efferocytosisChemistry & Biology 18, 97and proresolving lipid mediators such as RvE1 (Hong et al.,
2008).
DISCUSSION
In this report, we present evidence for the formation, complete
stereochemistry, and anti-inflammatory and proresolving ac-
tions of a novel aspirin-triggered DHA metabolome that pro-
duces AT-(NPD1/PD1). On the basis of physical and biological
properties in matching results with material from human cells,
murine exudates, and total organic syntheses, the complete
stereochemistry of AT-(NPD1/PD1) proved to be 10R,17R-
dihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid (Fig-
ures 1–4). The new aspirin-triggered product demonstrated
potent regulatory actions with leukocytes in vivo (Figure 5) and
reduced human PMN transendothelial migration and enhances
efferocytosis (Figure 6). This matching approach was deemed
necessary because typically less than nanogram amounts of
a given lipid mediator are produced in vivo, and >100 mg of6–987, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 981
Figure 6. AT-(NPD1/PD1) Limits Human PMN Transmigration Across Human Endothelial Cells and Enhances Human Macrophage Efferocy-
tosis of Apoptotic Human PMNs
(A) Neutrophils (106 cells/monolayer) were exposed to vehicle containing buffer or indicated concentrations of NPD1/PD1 (square), AT-(NPD1/PD1) (triangle),
D15-trans-AT-NPD1/AT-PD1 (diamond), or DHA (circle) (15min, pH 7.45, PBS/, 37C). Transmigration was initiated with addition of 108M LTB4 (90min, 37C).
Results are mean ± SEM obtained from 3–5 separate PMN donors, each point in triplicate.
(B) HUVECs were plated (0.2 3 106 cells/well) in an ECIS chamber for 24 hr. After 24 hr, PMN were isolated from human donors and incubated with AT-(NPD1/
PD1) or NPD1/PD1 (1 nM) for 15 min at 37C. LTB4 (10 nM) and PMN (10
6 cells) were then added to the HUVECS. Impedance changes were monitored using
Applied Biophysics ECIS software. Inset shows representative real-time tracing of impedance changes. Results are mean ± SEM of n = 3 separate donors and
HUVEC preparations, *p < 0.05. Using a two-way ANOVA, NPD1/PD1 was not significantly different from AT-NPD1/PD1 in reducing PMN transendothelial
migration (p > 0.05).
(C and D) Human macrophages (105 cells/well) were exposed to vehicle containing buffer or indicated concentrations of AT-(NPD1/PD1) (black triangles; C) or
NPD1/PD1 (black squares; D) (15 min, pH 7.45, PBS/, 37C). Uptake was initiated with addition of CFDA-labeled human apoptotic PMNs (3 3 105 cells/well,
60 min, 37C). Increase in efferocytosis was determined by monitoring total fluorescence from PMNs; mean ± SEM, *p < 0.05 versus vehicle, n = 3 healthy
subjects.
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conjugated double bonds that might give assignments for
stereochemistry (Serhan et al., 2006; Spite et al., 2009; Sun
et al., 2007).
Similar to the inversion of stereochemistry observed in the
aspirin-triggered lipoxin and resolvin pathways, we anticipated
thatAT-(NPD1/PD1)was likely topossess the carbon17Rstereo-
chemistry (Serhan et al., 2002), rather than the 17S chirality
present in NPD1/PD1 produced via a lipoxygenase reaction982 Chemistry & Biology 18, 976–987, August 26, 2011 ª2011 Elsevi(Bazan et al., 2010). Aspirin acetylation of COX-2 gives rise to
a catalytic activity that converts DHA to 17R-hydroxy–containing
products (Serhanet al., 2002). It is noteworthy topoint out that the
chirality at the C-10 position and the double bond geometry of
the triene system could not be reliably predicted on the basis of
LC-MS-MS lipidomics alone. As proposed for other potent poly-
unsaturated fatty acid–derived local mediators, it is likely that
the aspirin-triggered protectin pathway involves the conversion
of the hydroperoxide 17R-HpDHA to an epoxide intermediateer Ltd All rights reserved
Figure 7. Proposed Biosynthesis Scheme
for Aspirin-Triggered Protectins and AT-
(NPD1/PD1)
The stereochemistry and anti-inflammatory pro-
resolving bioactions of the members of this
pathway are determined (see text for details). The
stereochemistry of the epoxide intermediate is
shown in tentative configuration.
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ipated for these DHA-derived products, the stereochemical
mode of the enzymatic epoxide opening and the resulting triene
geometry needed to be verified by matching with isomers of
known stereochemistry. In order to achieve the complete stereo-
chemical assignments for the bioactive product(s), therefore, we
prepared several geometric isomers of the 10,17R-dihydroxydo-
cosa-4Z,7Z,11,13,15,19Z-hexaenoic acid,with specific changes
in R/S and Z/E configurations, and confirmed their stereochem-
istry using NMR spectroscopy (Figures 1 and 2). These synthetic
materials were also used for the direct matching and comparison
with biologically produced AT-(NPD1/PD1).
This aspirin-triggered pathway was first identified in resolution
phase inflammatory exudates and brain tissues of mice treated
with aspirin, and its basic structure was proposed (e.g.,
10,17R-dihydroxydocosa-4Z,7Z,11,13,15,19Z-hexaenoic acid)
(Marcheselli et al., 2003; Serhan et al., 2002). To confirm this
structural elucidation as well as to establish its complete stereo-
chemistry, it is essential to determine its physical and spectro-
scopic properties and compare them with those of candidates
with known stereochemistries using LC-UV-MS-MS (Yang
et al., 2011). Among these, 10S,17R-dihydroxydocosa-4Z,7Z,
11E,13E,15Z,19Z-hexaenoic acid (denoted as 10S,17R-NPD1/
PD1 isomer in Figure 3) is the nonsuperimposable mirror image
of NPD1/PD1 (10R,17S-dihydroxydocosa-4Z,7Z,11E,13E,15Z,
19Z-hexaenoic acid) (Serhan et al., 2006). Therefore, the two
are enantiomers, and as expected they display essentially iden-
tical chemical and physical properties in a symmetric environ-
ment (Carey and Sundberg, 2007). Indeed, 10S,17R-NPD1/
PD1 isomer was indistinguishable from NPD1/PD1 in terms of
chromatographic behavior (regular reverse phase liquid chroma-
tography retention times), UV, and tandem mass spectrum
patterns (Figure 3), yet proved biologically inactive (Serhan
et al., 2006) and did not coelute with the authentic human- or
mouse-derived AT material with LC-MS-MS (Figure 3A).
The present matching results indicate that, in this aspirin-trig-
gered DHA metabolome, the stereochemical configuration ofChemistry & Biology 18, 976–987, August 26, 2011AT-(NPD1/PD1) differs from that of
NPD1/PD1 only at carbon C-17, so the
two are diastereomers. Results from
earlier investigations have shown that
the differences in the MS and UV spectra
between lipidmediator diastereomers are
minimal, if any (Cla`ria and Serhan, 1995;
Spite et al., 2009; Sun et al., 2007), which
is consistent with the present results. For
example, tandem mass spectra of the
AT-17R–containing product and NPD1/
PD1 were essentially identical, and both
compounds displayed essentially the same triplet-band of
absorbance-shaped UV spectra with lmax
MeOH at 271 nm (Fig-
ures 3B and 3C), characteristic of ‘‘ol-triene-ol’’ structures (Bor-
geat and Samuelsson, 1979; Serhan et al., 2006). Some diaste-
reomers can possess different physical properties (Carey and
Sundberg, 2007) by which they can be physically differentiated.
Indeed, NPD1/PD1 and its aspirin-triggered isoform were well
separated using reverse phase lipid chromatography conditions
(Figure 3A). Diastereomers can give different biological proper-
ties, such as LTB4 and its natural isomer 12-epi-6-trans-LTB4,
which is log orders of magnitude less active (Borgeat and
Samuelsson, 1979; Lewis et al., 1981). Along these lines, the
aspirin-triggered diastereomer of NPD1/PD1 separated in chro-
matographic retention time directly compared to NPD1/PD1 but
shared its potent biological action (Figures 5 and 6).
We confirmed the actions of this aspirin-triggered response
with synthetic AT-(NPD1/PD1), which was potent, giving activity
at picogram amounts per mouse (Figure 5). TNF-a is a well-
known cytokine for its role in host defense; however, aberrant
or uncontrolled TNF-a responses are associated with several
inflammatory disorders (Dinarello, 2010). Although anti-TNF
therapies are widely available and in clinical use, it is becoming
increasingly clear that a complete blockade of TNF-a may pro-
mote adverse effects (Antoni and Braun, 2002), thus indicating
limitations in this approach (Lin et al., 2008). Importantly, AT-
(NPD1/PD1) is a potent regulator of PMN infiltration in vivo yet
did not completely block PMN recruitment, and hence is not
immunosuppressive. This is consistent with the unique counter-
regulatory actions of resolvins and specialized proresolving
mediators that do not compromise host defense via immune
suppression of effector cell function (Spite et al., 2009). Of
interest, with human PMN transmigration, 1–10 nM amounts of
AT-(NPD1/PD1) reduced LTB4-stimulated PMN transmigration,
and the D15-trans isomer of AT-(NPD1/PD1) was dramatically
less potent, underscoring the stereoselectivity of AT-(NPD1/
PD1) and the counterregulatory yet not immunosuppressive
actions of proresolving mediators. Along these lines, NPD1/PD1ª2011 Elsevier Ltd All rights reserved 983
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and regulates adiponectin (Gonza´lez-Pe´riz et al., 2009). Given
the present results, these processes may also be amenable to
AT-(NPD1/PD1) regulation.
In the biosynthesis of protectins, two endogenous forms of the
pathway exist, namely the aspirin-dependent as documented
here, and the lipoxygenase-initiated pathway for NPD1/PD1 (Ba-
zan, 2006; Bazan et al., 2010; Hong et al., 2003; Mukherjee et al.,
2004; Serhan et al., 2002). Hence, NPD1/PD1 joins the other
specialized anti-inflammatory– proresolving mediators that are
biosynthesized in both aspirin-dependent COX-2 routes (i.e.,
17R dominant) as well as lipoxygenase-initiated (17S-dominant
chirality) routes (Serhan, 2007). COX-2 is induced in human
PMN (Pouliot et al., 1998), and, in the presence of aspirin, the
acetylated enzyme converts DHA to a 17R-hydroperoxy–con-
taining DHA-derived intermediate 17R-HpDHA identified as
predominantly 17R-hydroxy-containing for its chirality at the
carbon 17 position (Serhan et al., 2002). Next, this hydroperoxide
intermediate of DHA is converted to both 17R-AT D-series resol-
vins and/or AT-(NPD1/PD1), as outlined in Figure 7. The biosyn-
thesis of active mediators carrying potent selective actions
involves conversion of the 17-hydroperoxy intermediate to a
16R,17R-epoxide that stereoselectively opens with an apparent
enzymatic production of AT-(NPD1/PD1) with the E,Z,Z triene
configuration (Figure 7). This double bond configuration proved
critical for potent bioactivity, because the D15-trans-AT-(NPD1/
PD1) isomer was essentially inactive.
Taken together, the results presented here confirm that the
structure of AT-(NPD1/PD1) is 10R,17R-dihydroxy-docosa-
4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid. Notably, this assign-
ment implies that the postulated enzyme-catalyzed opening
of the 16R,17R epoxide precursor of AT-(NPD1/PD1) would
proceed, in theory, via the introduction of the C-10 hydroxyl
from the same side as the epoxide oxygen atom to give the
10R,17R configuration, likely from water. This addition would
be opposite of the observed opening of the 16S,17S epoxide-
containing intermediate precursor of NPD1/PD1 that leads to
the 10R,17S configuration. This difference suggests that the
C-10 hydroxyl group is introduced via an enzyme-catalyzed
process and that the enzyme involved has a strong preference
for the formation of the 10R isomer, rather than the stereochem-
ical inversion of the epoxide precursor. These observations are
consistent with the formation of a rigid cationic-type interme-
diate at the enzyme active site, which undergoes stereospecific
attack by a water molecule from the same direction to afford
the 10R product. Also, the well-known antarafacial hydrogen
abstraction in LTA4 biosynthesis in this case to produce the
16,17-epoxide-containing intermediate from DHA might be
similar to the biosynthetic mechanism of LTA4 from 5-HpETE
as carried out by the 5-LOX (Shimizu et al., 1984; Wetterholm
et al., 1995). It is possible in the present scheme (Figure 7) that
the 17-hydroperoxide intermediate is converted to an epoxide
at C16-C17 position that could give to cis or trans epoxides
that require enzymatic processing in situ to give the potent active
stereochemical structure of AT-(NPD1/PD1). It is presently not
known whether 15-LOX, 12-LOX, or other lipoxygenases use
the same reaction mechanism as 5-LOX to produce cis-
epoxide-containing LTA4-like intermediates or whether unantic-
ipated new enzymatic mechanisms are involved.984 Chemistry & Biology 18, 976–987, August 26, 2011 ª2011 ElseviIn humans, low-dose aspirin triggers 15-epi-lipoxin produc-
tion, which reduces PMN infiltration following challenge (Morris
et al., 2009) and is formed in healthy subjects (Chiang et al.,
2004) as well as demonstrates reduced mortality from colorectal
cancer in long-term studies with daily aspirin (Rothwell et al.,
2010). Omega-3 EFA (EPA and DHA) at 1 g/day reduce cardio-
vascular mortality (Skulas-Ray et al., 2011). Thus, the combina-
tion of aspirin with omega-3 EFA and the aspirin-triggered me-
tabolome (i.e., AT-LX, AT-Rv) can have a beneficial therapeutic
impact in many diseases associated with ongoing inflammation
and host-mediated local tissue injury. Indeed, in a recent clinical
study, the combination of both aspirin (81 mg/day) and omega-3
EPA and DHA significantly reduced periodontal disease in
patients with chronic periodontitis (El-Sharkawy et al., 2010),
presumably by jump-starting resolution of periodontal inflamma-
tion via production of aspirin-triggered mediators and inhibition
of prostanoids (Van Dyke and Serhan, 2006). Hence, it is likely
that the aspirin inhibition of prostanoids and concomitant
biosynthesis of aspirin-triggered lipid mediators such as AT-lip-
oxins, AT-resolvins, and AT-protectins, including the new AT-
(NPD1/PD1) structure established herein, may each contribute
to some of these beneficial outcomes.
SIGNIFICANCE
The results of the present report establish the stereochem-
istry of AT-(NPD1/PD1) and several of its natural AT-isomers
generated by human leukocytes and murine tissues during
inflammation. Moreover, they demonstrate the potent ster-
eoselective anti-inflammatory and proresolving actions of
AT-(NPD1/PD1) in regulating PMN tissue accumulation and
provide new avenues to mark the impact of DHA and its
endogenous anti-inflammatory, proresolving mediators
(Serhan, 2007) that can be evoked with aspirin treatment.
Reducing PMN excess accumulation in tissues by these
new strategies can both shorten the resolution interval of
acute inflammation (Schwab et al., 2007; Serhan and Savill,
2005) and affect the transition from innate to adaptive immu-
nity without compromising host defense.
EXPERIMENTAL PROCEDURES
Materials
DHA was from Cayman Chemicals (Ann Arbor, MI). Calcium ionophore,
A23187, and aspirin (ASA) were purchased from Sigma (St. Louis, MO).
Zymosan A and 5-carboxyfluorescein diacetate, acetoxymethyl ester (CFDA)
were from Invitrogen (Carlsbad, CA). Recombinant murine TNF-a was
from Peprotech (Rocky Hill, NJ). PerCp-Cy5.5 anti-mouse CD11b (clone
M1/70) and FITC-anti-mouse-Ly6G (clone RB6-8C5) were purchased from
eBiosciences (San Diego, CA). Costar 5.0-mm transwells were from Corning
(Corning, NY). Human umbilical vein endothelial cells (HUVECs) were
purchased from Lonza Walkersville Inc. (Walkersville, MD).
LC-MS-MS–Based Mediator Lipidomics
LC-UV-MS-MS–based mediator lipidomics was performed using linear ion
trap quadrupole mass spectrometer (3200 QTRAP, Applied Biosystems,
Foster City, CA) equipped with two HPLC pumps (LC20AD, Shimazu,
Columbia, MD) coupled to a reverse phase column (Lunar C18, 150 mm 3
2 mm 3 3 mm, Phenomenex, Torrance, CA). The mobile phase consisted of
methanol:water:acetic acid 70:30:0.01 (v/v/v) with flow rate at 0.2 ml/min; after
25 min, the mobile phase was ramped to 100:0:0.01 over next 5 min, and kept
at 100:0:0.01 for 10 min to wash column. All intact cell incubations and in vivoer Ltd All rights reserved
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at least 30 min. Samples were extracted using C18 solid phase extraction
(SPE) and further analyzed using LC-MS-MS. Detailed procedures and LC-
MS-MS instrument settings as well as isolation, quantitation, and structural
determination of AT-(NPD1/PD1) and related lipid-derived mediators used in
the present experiments for elucidation of novel products were as reported
elsewhere (Hong et al., 2003; Serhan et al., 2002, 2006).
Preparation of Biologic AT-(NPD1/PD1)
Biologic AT-(NPD1/PD1) was isolated using murine exudates from zymosan-
initiated peritonitis as well as human PMN as described elsewhere (Serhan
et al., 2006). Briefly, peritonitis was initiated by intraperitoneal (i.p.) administra-
tion of 1mg of zymosan A in 1ml of sterile saline using 6–8-week-old FVBmale
mice (Charles River Laboratories, Wilmington, MA) that were fed Lab Diet
5001. After 24 hr, mice were sacrificed, and peritoneal exudates were har-
vested. All animal experiments were performed in accordance with the Har-
vard Medical School Standing Committee on Animals guidelines for animal
care (Protocol 02570). Exudate cells (50 3 106 cells/ml) were suspended in
1 ml of DPBS+/+ and were treated with aspirin (2 mM, 20 min, 37C) followed
by incubationwith HPLC-purifiedDHA (5 mg, 5min, 37C), andwere stimulated
with A23187 (5 mM, 20 min, 37C).
Human neutrophils (PMN) were isolated by dextran–Histopaque (1077)
double gradient from whole blood from healthy volunteers (deidentified)
who denied taking medications 2 weeks before donation (Partners Human
Research Committee Protocol no. 88–02642) and were anticoagulated with
heparin (1 U/ml) (Krishnamoorthy et al., 2010). Informed consent was obtained
from all donors. To induce COX-2, PMN (503 106 cells/incubation) were stim-
ulated with recombinant human TNF-a (10 ng/ml) for 4 hr at 37C as described
elsewhere (Pouliot et al., 1998). Afterward, aspirin (2 mM) was added (20 min,
37C) followed by A23187 (5 mM) and DHA (5 mg/ml) and incubated for 20 min
at 37C. Incubations were stopped with 2 volumes of cold methanol and were
kept at 20C for at least 30 min as above.
Total Synthesis and Stereochemical Characterization
of AT-(NPD1/PD1)
Several isomerically pure stereoisomers of NPD1/PD1 having either the
10R,17R or the 10S,17R stereochemistry were prepared by total synthesis,
by utilizing enantiomerically pure starting materials and by employing highly
stereocontrolled processes (see results in Figures 1 and 2). The hydroxyl
group stereochemistry at both the C-10 and C-17 positions was secured
from the corresponding protected glycidol derivative. The following isomers
were synthesized: 10R,17R-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hex-
anenoic acid, 10R,17R-dihydroxy-docosa-4Z,7Z,11E,13Z,15E,19Z-hexane-
noic acid, 10R,17R-dihydroxy-docosa-4Z,7Z,11E,13E,15E,19Z-hexanenoic
acid, 10S,17R-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexanenoic acid,
10S,17R-dihydroxy-docosa-4Z,7Z,11E,13Z,15E,19Z-hexanenoic acid, and
(VI) 10S,17R-dihydroxy-docosa-4Z,7Z,11E,13E,15E,19Z-hexanenoic acid.
The methyl ester of each isomer was fully characterized by high field NMR
spectroscopy that unambiguously confirmed its double bond geometry.
Acute Inflammatory Exudates: Murine Peritonitis
Peritonitis was performed as described above. Briefly, themethyl ester of each
new synthetic stereoisomer or DHA was administered via intraperitoneal
injection (i.p.) with either zymosan A (100 mg/ml) or TNF-a (500 ng/ml) in 1 ml
of saline. After 4 hr, the mice were sacrificed in accordance with the Harvard
Medical Area Standing Committee on Animals (Protocol no. 02570). Peritoneal
lavages were harvested immediately, cells were enumerated, cell viability was
determined using Trypan blue exclusion, and differential cell counts were
monitored by Wright-Giemsa staining and flow cytometry (BD FACS Canto).
PMN were identified based on LY6G+CD11b+ staining and analyzed via
FlowJo Software.
Human Neutrophil Transmigration
HUVEC confluent monolayers were grown on polycarbonate membranes
(5.0-mm pore size, 0.1% gelatin) for 24 hr as described elsewhere (Gimbrone
et al., 1974; Serhan et al., 2006).
PMN were isolated as described above and were fluorescently labeled with
CFDA for 20 min at room temperature. Excess CFDA was removed (1000 rpm,Chemistry & Biology 18, 9710 min, RT), and PMN were incubated with either vehicle-containing buffer or
compound for 15 min at 37C. A chemotactic gradient was established by
placing the transwell inserts in media containing 10 nM LTB4. PMN (10
6 cells)
were added in the upper chambers, and transmigrationwas performed at 37C
for 90 min. Transmigrated PMN were quantified via fluorescence using
a Victor3 plate reader.
Electric Cell-Substrate Impedance Sensing
Human PMN and human endothelial interactions were assessed using
changes in electric cell-substrate impedance sensing (ECIS) 1600R system
(Applied Biophysics). ECIS measures real-time cellular responses by moni-
toring impedance changes of cells placed atop specific electrodes (Tsikitis
et al., 2004; Wang et al., 2010). HUVECs (0.2 3 106 cells/well) were cultured
to confluence (24 hr) on an 8W10E+ electrode array. Next, fresh human PMN
were isolated (106 cells/well) following venipuncture and exposed to either
vehicle containing buffer (EMB serum free media), AT-(NPD1/PD1) (1 nM), or
NPD1/PD1 (1 nM) for 15min at 37C. PMNwere added to eachwell and imped-
ance baseline was set at 4 kHz. Cells were then exposed to LTB4 (10 nM) and
changes in impedance reflecting transendothelial PMN migration were moni-
tored in real time via ECIS software (v1.2.35.0) for 45min, at 37C in 0.5%CO2.
Efferocytosis: Uptake of Apoptotic PMN by Human Macrophages
Monocytes were isolated from human whole blood and cultured in RPMI with
10 ng/ml human GM–CSF (R&D Systems) at 37C for 7 days (Geissler et al.,
1989; Krishnamoorthy et al., 2010). For efferocytosis of apoptotic PMNs,
isolated human PMNs were allowed to undergo apoptosis in RPMI (2 3
106 cells/ml) for 16–18 hr then labeled with carboxyfluorescein diacetate
(10 mM, 30 min at 37C; Molecular Probes). Macrophages (1.0 3 105 cells/
well) were incubated with either AT-(NPD1/PD1), NDP1/PD1 or vehicle
(15 min at 37C). Apoptotic PMNs were added at 1:3 (Macrophage:PMN),
and incubations carried out at 37C for 60 min. Supernatants were aspirated
and trypan blue (0.03% in DPBS+/+ for 60 s) was added to quench extra-
cellular fluorescence. Fluorescence was measured using a M3 SpectraMax
plate reader (Molecular Devices).
Statistical Analysis
The significance of differences between groups was evaluated using the
two-tailed Student’s t test. In addition, one-way and two-way ANOVA were
carried out for evaluating significance of difference among more than two
groups and for dose-response curves; p values of less than 0.05 were
considered statistically significant.
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